This study was conducted to evaluate the possible synergistic cytotoxic combination effect of LY: as a specific phosphatidylinositide-3-kinase (PI3K) inhibitor, and TAM: as an established BC/ER+ drug. This evidence concerns the gene ESR1 and breast cancer.